Member Info for chester18

As has been said on every board for every listed company. “Nothing goes up in a straight line”.

The market makers use one or two reasonably decent sized sells to drop the price and then smaller sells they drop it even further. It’s a well trodden path and it’s no surprise on such a steep rise.

We have seen a real interest in the Scancell stock and that is not going to change now we have USA Fast Track Designation.

News on quite a few things is overdue and there must be a reason why the company are keeping silent at the moment.

GLA

Hi Wildforce / GF123

Every time Scancell produce a piece of positive news the potential SP rise was sold into until the price retreated. Every move forward was squashed before any momentum could be applied. Time and time again the prospects looked good and someone sold into the news.

So in effect this is the first opportunity the market has had to progress the SP in straight line and in a positive way.

I think you can say that now the ‘overhang’ has dried up, I think the SP has its MoJo back ….., 🤞

Perfect C11, a fold-up car ……

I’m ordering one as soon as we hit 40p 😂

Very nice if like speed and showing off 😂

I had an Escort XR3i in my late twenties that was fast enough for me.

My hope is that Immunobody and ModiTope turn out to be the cancer crushers we have waited and prayed for. The excitement of a high SP would also be fantastic 👊👊

C11

That would be nice if only.

My car is now in its 12th year so it would be very acceptable if it could be replaced by something more up to date.

Saying that, the bulk of my Scancell shares are older 🤣🤣

Good morning each and all.

It is looking very likely that 18.0p will soon be in the rear mirror and I’m heartened by the solidity of the buying and the general increase in the number of transactions per day.

An important factor for me is the fact that we are still under £200m Market Cap.

Trinity Delta have deliberately kept there current target to the same £330m MCap as there last report, which to be honest is not a true reflection of where Scancell are with FDA trial application approval and the added Fast Track status.

It will only take one small piece of positive news and we should be knocking on that low priced 32p target.

Importantly that piece of news is probably already overdue and could arrive at any time.

GLA

I think proving out iSCIB1+ by keeping total control would be amazing only if Scancell was just a one trick pony.

We have so many other product's that need development money. I don’t want SC134 or SCiB2 or Modi1 / 2 or new GlyMab discovery being postponed until 2029.

Do a deal get some major finance in the bank account and process all of the above, would be my choice.

Redmile and Vulpes must have had the same thoughts.

I would hope that we are not all being delusional in thinking that at least one of the suggested Big Pharma companies do actually want to own Immunobody.

I remember the question being put to Phil by one of the institutional investors. It was during the Q&A after a presentation.

I think the premise was that the data suggested it was robust enough to use finance over giving the technology away on the cheap. Add to this all the talk of a NasDaq listing and it would give the impression that our Board are considering going it alone’.

I would think that Redmile and to some extent Vulpes, are more interested with a return on investment sooner rather than in another 2/3 years.

I think we would all prefer a solid pay day now rather than waiting.

Totally agree PLP

It is all conjecture but some of our predictions must be close to reality.

What we know is that it’s going to be awesome…….🥳🥳

Sorry I got carried away then …. What will be will be but I hope it’s Mega 😂😂

Balerno

“The more the merrier” …….

I hope they do want to take out Scancell and they can throw their hat in the ring with, BMS, Merck, BionTech plus other unknow potential suitors.

If what we fantasise about is actually happening in reality, I for one cannot imagine the potential numbers that would win that battle of ownership.

I would say anyone with 100,000 or more shares in that scenario would hold a life changing amount of value.

“ Vision or Reality “…… Reality please 😉

Hi Dragon101

Yes, the research here has shown him to be that very man.

Huge experience in developing and taking new innovations through clinical trials.

To have him advising is a fantastic achievement by Scancell and Co.

If it reaches 42 you could be pulled in by the Vogon’s……

Which would not be nice …so stick to 34 👊

Thank you Miavoce

That’s one impressive list of well regarded Immunologists, Oncologists and Bio-Pharma experience.

If anyone hasn’t taken a look I advise you do because those are all people at the top of their game.

Scancell has to have something that they all see as worthy and potentially very significant.

Where can I see the full CAB list. I know it was on the website but having just looked I could not find it.

Any suggestions?

There will definitely be further PFS data released by the end of June. This is now all about landing a deal or securing finance.

Our CEO will do what is necessary to ensure the quality of the data in his news releases or presentation's.

This is presuming that we will still need to impress Large Pharma because an agreement might already be in place by then.

This is a very solid rise from the 9.5p / 10.5p range that persisted for over 4 months.

Investor’s that are just tuning in to Scancell at this transitional time must see that the potential is definitely there to double or treble their money.

Next 7.1/2 weeks will produce news on approvals ( MHRA + EMA ), ModiTope trial ( Modi1 ), another iSCIB1+ update, GenMab Milestone and most importantly the Finance / Partnership / Deal.

Why all of the above ?

We’ve been told that the SCOPE Phase3 Registrational Trail will start in 2026, therefore it follows that the pathway to that trial ( partnership / financing ) must be concluded or at the very least, established by the beginning of H2/26.

For the trial to start in December the lead in must be 5 or 6 months once all approvals have been concluded.

MelimmSciMab or ‘Sciblatta 1’

Perfect size for filling a 2026 ISA pot.

Obviously the Scancell story is now reaching a much wider audience and for anyone new who is interested in finding a junior or baby bio with an incredible upside, Scancell has to fit the bill.

From now until the end of June there is a tonne of news to land and if it all rolls out with a positive slants the share price will easily push through the 20p’s.

GLA

First time for a while that we’ve seen 17p.

Not a vast amount of shares but still a very significant move forward.

If positive news lands while we’re still rising the daily volume should take off.

Yes Ray

The kind of problem any CEO would relish ……. It’s only tough in the sense that we don’t want anything given away or be overly greedy.

I wish C7 could have been here to enjoy this current excitement, he would be multi-posting without a doubt…. 👊👊